# Biotech Daily Digest ‚Äî 2025-10-22

**51 items from 3 sources**

## Summary by Source

- Endpoints News: 15 items
- Fierce Biotech: 11 items
- arXiv q-bio: 25 items


## Endpoints News

- **[Starna Therapeutics raises $44M to advance in vivo CAR-T programs after early clinical data](https://endpoints.news/starna-therapeutics-raises-44m-to-advance-in-vivo-car-t-programs-after-early-clinical-data/)**  
  _Wed, 22 Oct 2025 14:19:51 +0000_  
  The global race to develop in vivo CAR-T therapies that could replace onerous cell therapies with simpler, safer infusions continues to heat up, and now a Chinese biotech startup has quietly begun clinical tests of ...

- **[Japan‚Äôs Fast Track Initiative announces new $130M venture fund](https://endpoints.news/japans-fast-track-initiative-announces-new-130m-venture-fund/)**  
  _Wed, 22 Oct 2025 14:00:10 +0000_  
  Japanese venture firm Fast Track Initiative unveiled on Tuesday its fourth fund of about $130 million, or ¬•20 billion. The firm is riding a wave of interest since Shimon Sakaguchi, the founder of one of ...

- **[Summit raises $500M, with more than half coming from its C-suite](https://endpoints.news/summit-raises-500m-with-more-than-half-coming-from-its-c-suite/)**  
  _Wed, 22 Oct 2025 13:35:53 +0000_  
  Summit Therapeutics announced a $500 million private placement on Wednesday, more than half of which comes from members of its C-suite.

 The company‚Äôs billionaire co-CEO Bob Duggan, along with co-CEO Maky Zanganeh, the CFO/COO and ...

- **[Sanofi reveals Phase 2 rare disease win from Inhibrx buyout](https://endpoints.news/sanofi-reveals-phase-2-rare-disease-win-from-inhibrx-buyout/)**  
  _Wed, 22 Oct 2025 13:27:00 +0000_  
  Sanofi on Wednesday reported a successful Phase 2 result for the rare disease drug it acquired in its buyout of Inhibrx last year.

 The program, called efdoralprin alfa and formerly known as INBRX-101, achieved all ...

- **[Alector‚Äôs GSK-partnered dementia drug flunks Phase 3, plots to halve workforce](https://endpoints.news/alectors-gsk-partnered-dementia-drug-flunks-phase-3-plots-to-halve-workforce/)**  
  _Wed, 22 Oct 2025 12:58:17 +0000_  
  Alector said one antibody from its $700 million upfront deal with GSK missed a key endpoint in a Phase 3 study in dementia. The biotech will end work on that asset and ...

- **[Sanofi backs immunology startup, which raises $183M Series C for lead drug's pivotal trial](https://endpoints.news/sanofi-backs-immunology-startup-which-raises-183m-series-c-for-lead-drugs-pivotal-trial/)**  
  _Wed, 22 Oct 2025 11:00:41 +0000_  
  An immunology startup has a hefty round of cash to get its lead program through a pivotal study and advance another preclinical drug into human testing.

 Electra Therapeutics on Wednesday closed a $183 million Series ...

- **[Ipsen to buy ImCheck for ‚Ç¨350M to get 'superfamily' of immunotherapies](https://endpoints.news/ipsen-to-buy-imcheck-for-e350m-to-get-superfamily-of-immunotherapies/)**  
  _Wed, 22 Oct 2025 10:28:46 +0000_  
  Ipsen will buy fellow French biotech ImCheck Therapeutics for ‚Ç¨350 million upfront ($406 million), adding to a series of M&A deals that have steadily buoyed the industry's optimism in recent weeks.

 The deal could balloon ...

- **[Takeda makes major bispecific, ADC pact with Innovent for $1.2B upfront](https://endpoints.news/takeda-makes-major-bispecific-adc-pact-with-innovent-for-1-2b-upfront/)**  
  _Wed, 22 Oct 2025 07:31:10 +0000_  
  Takeda, which is undergoing a big pipeline transformation, has forged one of the year's largest upfront R&D pacts. And like more than a third of this year's biopharma licensing deals, it involves a Chinese drug ...

- **[10x Genomics files patent suits against Illumina](https://endpoints.news/10x-genomics-files-patent-suits-against-illumina/)**  
  _Wed, 22 Oct 2025 02:01:04 +0000_  
  10x Genomics on Tuesday filed two lawsuits against Illumina, alleging the DNA sequencing giant infringed patents as part of a push to broaden its offerings.

 Both cases were filed in Delaware federal ...

- **[Genmab was one of three bidders before inking $8B Merus acquisition](https://endpoints.news/genmab-was-one-of-three-bidders-before-inking-8b-merus-acquisition/)**  
  _Wed, 22 Oct 2025 01:54:06 +0000_  
  There were multiple bidders at the table for the fourth-largest biopharma acquisition of 2025, according to a regulatory filing, bucking the trend of single-suitor processes for many other deals this year.

 Last month, Genmab won ...

- **[Grail raises $325M from Hims and others ahead of FDA bid](https://endpoints.news/grail-raises-325m-from-hims-and-others-ahead-of-fda-bid/)**  
  _Tue, 21 Oct 2025 18:46:51 +0000_  
  Grail has raised $325 million in a private placement, bolstering the company's balance sheet as it prepares to ask the FDA to approve its blood test that's designed to detect dozens of cancers.

 The California ...

- **[Regeneron reaches patent deal with Celltrion over Eylea biosimilar](https://endpoints.news/regeneron-reaches-patent-deal-with-celltrion-over-eylea-biosimilar/)**  
  _Tue, 21 Oct 2025 18:16:52 +0000_  
  Celltrion can sell a biosimilar version of Regeneron‚Äôs Eylea in the US at the end of 2026, following a patent deal between the two companies that also clears the path for more competition against the ...

- **[As China moves beyond ‚Äòme-too,‚Äô do Western regulators need to reconsider?](https://endpoints.news/as-china-moves-beyond-me-too-do-western-regulators-need-to-reconsider/)**  
  _Tue, 21 Oct 2025 16:38:56 +0000_  
  BERLIN ‚Äî At Europe‚Äôs largest cancer conference, Sunday's main stage belonged to China.

 Medical conferences use their keynote sessions to highlight results from what the top researchers in the world think are the most important trials ...

- **[Neuphoria scraps social anxiety drug; Minerva doubles down on schizophrenia therapy](https://endpoints.news/neuphoria-scraps-social-anxiety-drug-minerva-doubles-down-on-schizophrenia-therapy/)**  
  _Tue, 21 Oct 2025 15:03:33 +0000_  
  Plus, news about Syncona, Ventus Therapeutics, Roche, Disc Medicine, Atai Life Sciences, Lexeo Therapeutics, Novartis, Vivace Therapeutics, Kura Oncology, Corbus and J&J:

 üíº Neuphoria Therapeutics‚Äô social anxiety drug fails Phase 3: The biotech is discontinuing ...

- **[GSK, Spero reveal full Phase 3 data for oral antibiotic, set for end-of-year filing](https://endpoints.news/gsk-spero-reveal-full-phase-3-data-for-oral-antibiotic-set-for-end-of-year-filing/)**  
  _Tue, 21 Oct 2025 14:45:04 +0000_  
  GSK and Spero Therapeutics are taking their oral antibiotic to the FDA after reporting the full Phase 3 non-inferiority data.

 The companies said Monday that tebipenem HBr performed no worse than ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/sanofis-17b-rare-disease-bet-beats-csls-zemaira-phase-2-face" hreflang="en">Sanofi's $1.7B rare disease bet beats CSL's Zemaira in phase 2 face-off</a>](https://www.fiercebiotech.com/biotech/sanofis-17b-rare-disease-bet-beats-csls-zemaira-phase-2-face)**  
  _Oct 22, 2025 10:13am_  
  Sanofi‚Äôs $1.7 billion rare disease bet has delivered a phase 2 win. Efdoralprin alfa beat the standard of care on primary and key secondary endpoints, positioning the drugmaker to talk to regulators about the next steps.

- **[<a href="https://www.fiercebiotech.com/biotech/takeda-pays-innovent-12b-upfront-rights-2-cancer-candidates" hreflang="en">Takeda pays Innovent $1.2B upfront, offers whopping $10B-plus in biobucks for cancer assets</a>](https://www.fiercebiotech.com/biotech/takeda-pays-innovent-12b-upfront-rights-2-cancer-candidates)**  
  _Oct 22, 2025 9:02am_  
  Takeda is paying Innovent Biologics $1.2 billion upfront for rights to two cancer candidates. The deal, which includes $10.2 billion in milestones, puts the biologics at the center of Takeda‚Äôs efforts to establish growth drivers for a post-Entyvio era.

- **[<a href="https://www.fiercebiotech.com/medtech/hologic-go-private-183b-acquisition-blackstone-and-tpg" hreflang="en">Hologic to go private with $18.3B acquisition by Blackstone and TPG</a>](https://www.fiercebiotech.com/medtech/hologic-go-private-183b-acquisition-blackstone-and-tpg)**  
  _Oct 22, 2025 8:30am_  
  In one of the biggest healthcare acquisitions of its kind this year, medtech diagnostics specialist Hologic will go private following its sale to Blackstone and TPG in a deal valued at more than $18.3 billion.

- **[<a href="https://www.fiercebiotech.com/biotech/some-encouraging-signs-market-electra-shines-183m-fundraise-rare-disease-trial" hreflang="en">'Some encouraging signs in the market': Electra shines with $183M fundraise for rare disease trial</a>](https://www.fiercebiotech.com/biotech/some-encouraging-signs-market-electra-shines-183m-fundraise-rare-disease-trial)**  
  _Oct 21, 2025 8:33pm_  
  Electra Therapeutics is incandescent, glowing on the heels of a $183 million series C financing intended to fuel the biotech‚Äôs just-launched pivotal trial for its rare disease candidate.

- **[<a href="https://www.fiercebiotech.com/biotech/terns-mothballs-obesity-program-after-phase-2-data-fall-short" hreflang="en">Terns mothballs obesity program after phase 2 data fall short</a>](https://www.fiercebiotech.com/biotech/terns-mothballs-obesity-program-after-phase-2-data-fall-short)**  
  _Oct 22, 2025 4:51am_  
  Terns Pharmaceuticals has shelved its oral GLP-1 obesity candidate after a phase 2 trial delivered a mix of weight loss and tolerability that fell short of expectations and evidence the asset causes liver injuries.

- **[<a href="https://www.fiercebiotech.com/biotech/esmo-modernas-oncology-efforts-make-sense-while-government-skeptical-vaccines" hreflang="en">ESMO: Moderna's oncology efforts 'make sense' while government skeptical of vaccines</a>](https://www.fiercebiotech.com/biotech/esmo-modernas-oncology-efforts-make-sense-while-government-skeptical-vaccines)**  
  _Oct 19, 2025 4:36am_  
  Moderna‚Äôs efforts to advance its cancer pipeline ‚Äúmake sense‚Äù against the backdrop of a more skeptical U.S. government attitude to infectious disease vaccines, the company‚Äôs oncology chief told Fierce.

- **[<a href="https://www.fiercebiotech.com/biotech/british-biotech-elevates-stealth-70m-series-and-midstage-arthritis-asset" hreflang="en">British biotech emerges with $70M series A and midstage arthritis asset</a>](https://www.fiercebiotech.com/biotech/british-biotech-elevates-stealth-70m-series-and-midstage-arthritis-asset)**  
  _Oct 21, 2025 5:23pm_  
  With $70 million and a phase 2 ready asset in hand, British biotech Elevara Medicines has emerged to try to revolutionize the treatment of rheumatoid arthritis.

- **[<a href="https://www.fiercebiotech.com/biotech/we-need-pick-lane-lilly-oncology-president-weighs-fda-cancer-drug-policies" hreflang="en">‚ÄòWe need to pick a lane‚Äô: Lilly oncology president weighs in on FDA cancer drug policies</a>](https://www.fiercebiotech.com/biotech/we-need-pick-lane-lilly-oncology-president-weighs-fda-cancer-drug-policies)**  
  _Oct 21, 2025 11:57am_  
  ‚ÄúWe need to pick a lane here as a country. Which one do we care more about? Proving survival, which means no crossover; or getting U.S. participation, where crossover is a pretty important incentive,‚Äù Eli Lilly‚Äôs oncology chief, Jake Van Naarden, said in an interview.

- **[<a href="https://www.fiercebiotech.com/biotech/gsk-unveils-pivotal-data-oral-antibiotic-ahead-fda-filing" hreflang="en">GSK unveils positive pivotal data for Spero's once-rejected oral antibiotic</a>](https://www.fiercebiotech.com/biotech/gsk-unveils-pivotal-data-oral-antibiotic-ahead-fda-filing)**  
  _Oct 21, 2025 10:36am_  
  GSK and Spero Therapeutics have shared phase 3 results on their antibiotic candidate, revealing that the oral therapy closely matched the intravenous incumbent in a trial that could support filings for approval.

- **[<a href="https://www.fiercebiotech.com/biotech/neuphoria-nixes-social-anxiety-program-and-starts-strategic-review-after-ph-3-flop" hreflang="en">Neuphoria nixes social anxiety program and starts strategic review after phase 3 flop</a>](https://www.fiercebiotech.com/biotech/neuphoria-nixes-social-anxiety-program-and-starts-strategic-review-after-ph-3-flop)**  
  _Oct 21, 2025 10:29am_  
  Neuphoria Therapeutics‚Äô lead candidate has failed to improve social anxiety symptoms in a late-stage trial, prompting the biotech to discontinue the program and launch a strategic review of its business.

- **[<a href="https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025" hreflang="en">Fierce Biotech Layoff Tracker 2025: Galapagos to shutter cell therapy unit; Kezar plots cuts</a>](https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025)**  
  _Dec 23, 2024 11:52am_  
  As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.


## arXiv q-bio

- **[The Standard Model of the Retina](https://arxiv.org/abs/2510.17820)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2510.17820v1 Announce Type: new 
Abstract: The scientific study of the retina has reached a remarkable state of completion. We can now explain many aspects of early visual processing based on a relatively simple model of neural circuitry in the retina. The same model, with different parameters, produces a great‚Ä¶

- **[A Biophysical-Model-Informed Source Separation Framework For EMG Decomposition](https://arxiv.org/abs/2510.17822)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2510.17822v1 Announce Type: new 
Abstract: Recent advances in neural interfacing have enabled significant improvements in human-computer interaction, rehabilitation, and neuromuscular diagnostics. Motor unit (MU) decomposition from surface electromyography (sEMG) is a key technique for extracting neural drive in‚Ä¶

- **[Speak to a Protein: An Interactive Multimodal Co-Scientist for Protein Analysis](https://arxiv.org/abs/2510.17826)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2510.17826v1 Announce Type: new 
Abstract: Building a working mental model of a protein typically requires weeks of reading, cross-referencing crystal and predicted structures, and inspecting ligand complexes, an effort that is slow, unevenly accessible, and often requires specialized computational skills. We in‚Ä¶

- **[Brain-Language Model Alignment: Insights into the Platonic Hypothesis and Intermediate-Layer Advantage](https://arxiv.org/abs/2510.17833)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2510.17833v1 Announce Type: new 
Abstract: Do brains and language models converge toward the same internal representations of the world? Recent years have seen a rise in studies of neural activations and model alignment. In this work, we review 25 fMRI-based studies published between 2023 and 2025 and explicitly‚Ä¶

- **[CBINNS: Cancer Biology-Informed Neural Network for Unknown Parameter Estimation and Missing Physics Identification](https://arxiv.org/abs/2510.17920)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2510.17920v1 Announce Type: new 
Abstract: The dynamics of tumor-immune interactions within a complex tumor microenvironment are typically modeled using a system of ordinary differential equations or partial differential equations. These models introduce some unknown parameters that need to be estimated accurate‚Ä¶

- **[Relation between in vitro microbial fermentations and in vivo performance in pigs selected for their residual feed intake](https://arxiv.org/abs/2510.18401)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2510.18401v1 Announce Type: new 
Abstract: Bioinformatic analysis of microbiota revealed that certain metabolic pathways are associated with low- and high- residual feed intake (HRFI and LRFI), such as the amino-acid biosynthesis pathway and the tRNA-aminoacyl synthesis pathway. The latter is associated with inc‚Ä¶

- **[Decoding Dynamic Visual Experience from Calcium Imaging via Cell-Pattern-Aware SSL](https://arxiv.org/abs/2510.18516)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2510.18516v1 Announce Type: new 
Abstract: Self-supervised learning (SSL) holds a great deal of promise for applications in neuroscience, due to the lack of large-scale, consistently labeled neural datasets. However, most neural datasets contain heterogeneous populations that mix stable, predictable cells with h‚Ä¶

- **[A Multi-Evidence Framework Rescues Low- Power Prognostic Signals and Rejects Statistical Artifacts in Cancer Genomics](https://arxiv.org/abs/2510.18571)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2510.18571v1 Announce Type: new 
Abstract: Motivation: Standard genome-wide association studies in cancer genomics rely on statistical significance with multiple testing correction, but systematically fail in underpowered cohorts. In TCGA breast cancer (n=967, 133 deaths), low event rates (13.8%) create severe p‚Ä¶

- **[Mechanical activity enables patterning and discrimination at the immune synapse](https://arxiv.org/abs/2510.18771)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2510.18771v1 Announce Type: new 
Abstract: Immune cells recognize and discriminate antigens through immunological synapses - dynamic intercellular junctions exhibiting highly organized receptor-ligand patterns. While much work has focused on molecular kinetics and passive mechanisms of pattern formation, the rol‚Ä¶

- **[Protein generation with embedding learning for motif diversification](https://arxiv.org/abs/2510.18790)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2510.18790v1 Announce Type: new 
Abstract: A fundamental challenge in protein design is the trade-off between generating structural diversity while preserving motif biological function. Current state-of-the-art methods, such as partial diffusion in RFdiffusion, often fail to resolve this trade-off: small perturb‚Ä¶

- **[Triangle Multiplication Is All You Need For Biomolecular Structure Representations](https://arxiv.org/abs/2510.18870)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2510.18870v1 Announce Type: new 
Abstract: AlphaFold has transformed protein structure prediction, but emerging applications such as virtual ligand screening, proteome-wide folding, and de novo binder design demand predictions at a massive scale, where runtime and memory costs become prohibitive. A major bottlen‚Ä¶

- **[Information Capacity of EEG: Theoretical and Computational Limits of Recoverable Neural Information](https://arxiv.org/abs/2510.17841)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2510.17841v1 Announce Type: cross 
Abstract: Electroencephalography (EEG) is widely used to study human brain dynamics, yet its quantitative information capacity remains unclear. Here, we combine information theory and synthetic forward modeling to estimate the mutual information between latent cortical sources‚Ä¶

- **[Self-Evidencing Through Hierarchical Gradient Decomposition: A Dissipative System That Maintains Non-Equilibrium Steady-State by Minimizing Variational Free Energy](https://arxiv.org/abs/2510.17916)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2510.17916v1 Announce Type: cross 
Abstract: The Free Energy Principle (FEP) states that self-organizing systems must minimize variational free energy to persist, but the path from principle to implementable algorithm has remained unclear. We present a constructive proof that the FEP can be realized through exac‚Ä¶

- **[Benchmarking Probabilistic Time Series Forecasting Models on Neural Activity](https://arxiv.org/abs/2510.18037)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2510.18037v1 Announce Type: cross 
Abstract: Neural activity forecasting is central to understanding neural systems and enabling closed-loop control. While deep learning has recently advanced the state-of-the-art in the time series forecasting literature, its application to neural activity forecasting remains li‚Ä¶

- **[Enhancing mortality prediction in cardiac arrest ICU patients through meta-modeling of structured clinical data from MIMIC-IV](https://arxiv.org/abs/2510.18103)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2510.18103v1 Announce Type: cross 
Abstract: Accurate early prediction of in-hospital mortality in intensive care units (ICUs) is essential for timely clinical intervention and efficient resource allocation. This study develops and evaluates machine learning models that integrate both structured clinical data an‚Ä¶

- **[Quantification of dual-state 5-ALA-induced PpIX fluorescence: Methodology and validation in tissue-mimicking phantoms](https://arxiv.org/abs/2510.18387)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2510.18387v1 Announce Type: cross 
Abstract: Quantification of protoporphyrin IX (PpIX) fluorescence in human brain tumours has the potential to significantly improve patient outcomes in neuro-oncology, but represents a formidable imaging challenge. Protoporphyrin is a biological molecule which interacts with th‚Ä¶

- **[HeFS: Helper-Enhanced Feature Selection via Pareto-Optimized Genetic Search](https://arxiv.org/abs/2510.18575)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2510.18575v1 Announce Type: cross 
Abstract: Feature selection is a combinatorial optimization problem that is NP-hard. Conventional approaches often employ heuristic or greedy strategies, which are prone to premature convergence and may fail to capture subtle yet informative features. This limitation becomes es‚Ä¶

- **[Inheritance entropy quantifies epigenetic regulation of cell-cycle exit in human bone marrow stromal cells](https://arxiv.org/abs/2510.18589)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2510.18589v1 Announce Type: cross 
Abstract: Human bone marrow stromal cells (BMSC) include skeletal stem cells with ground-breaking therapeutic potential. However, BMSC colonies have very heterogeneous in vivo behaviour, due to their different potency; this unpredictability is the greatest hurdle to the develop‚Ä¶

- **[On Biologically Plausible Learning in Continuous Time](https://arxiv.org/abs/2510.18808)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2510.18808v1 Announce Type: cross 
Abstract: Biological learning unfolds continuously in time, yet most algorithmic models rely on discrete updates and separate inference and learning phases. We study a continuous-time neural model that unifies several biologically plausible learning algorithms and removes the n‚Ä¶

- **[From Possibility to Precision in Macromolecular Ensemble Prediction](https://arxiv.org/abs/2505.01919)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2505.01919v2 Announce Type: replace 
Abstract: Proteins and other macromolecules exist not in a single state but as dynamic ensembles of interconverting conformations, which are essential for catalysis, allosteric regulation, and molecular recognition. While AI-based structure predictors like AlphaFold have revo‚Ä¶

- **[Steering Generative Models with Experimental Data for Protein Fitness Optimization](https://arxiv.org/abs/2505.15093)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2505.15093v2 Announce Type: replace 
Abstract: Protein fitness optimization involves finding a protein sequence that maximizes desired quantitative properties in a combinatorially large design space of possible sequences. Recent advances in steering protein generative models (e.g., diffusion models and language‚Ä¶

- **[Driving factors of auditory category learning success](https://arxiv.org/abs/2506.01508)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2506.01508v2 Announce Type: replace 
Abstract: Our brain learns to update its mental model of the environment by abstracting sensory experiences for adaptation and survival. Learning to categorize sounds is one essential abstracting process for high-level human cognition, such as speech perception, but it is als‚Ä¶

- **[Brain-Like Processing Pathways Form in Models With Heterogeneous Experts](https://arxiv.org/abs/2506.02813)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2506.02813v2 Announce Type: replace 
Abstract: Examples of such pathways can be found in the interactions between cortical and subcortical networks during learning, or in sub-networks specializing for task characteristics such as difficulty or modality. Despite the large role these pathways play in cognition, th‚Ä¶

- **[Topological Sequence Analysis of Genomes: Category theory Approaches](https://arxiv.org/abs/2507.08043)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2507.08043v2 Announce Type: replace 
Abstract: Sequence data, such as DNA, RNA, and protein sequences, exhibit intricate, multi-scale structures that pose significant challenges for conventional analysis methods, particularly those relying on alignment or purely statistical representations. In this work, we intr‚Ä¶

- **[One protein is all you need](https://arxiv.org/abs/2411.02109)**  
  _Wed, 22 Oct 2025 00:00:00 -0400_  
  arXiv:2411.02109v2 Announce Type: replace-cross 
Abstract: Generalization beyond training data remains a central challenge in machine learning for biology. A common way to enhance generalization is self-supervised pre-training on large datasets. However, aiming to perform well on all possible proteins can limit a mode‚Ä¶
